Sevelamer in a diabetologist's perspective: A phosphate-binding resin with glucose-lowering potential

A. Brønden; M. Hansen; D. P. Sonne; U. Rohde; T. Vilsbøll; Filip K. Knop

doi:10.1111/dom.12355

Sevelamer in a diabetologist's perspective: A phosphate-binding resin with glucose-lowering potential

A. Brønden, M. Hansen, D. P. Sonne, U. Rohde, T. Vilsbøll, Filip K. Knop^*

^*Corresponding author for this work

Research output: Contribution to journal › Review › Research › peer-review

10 Citations (Scopus)

Abstract

Sevelamer is a calcium-free and metal-free phosphate-binding oral drug used in the management of hyperphosphataemia in chronic kidney disease. Preclinical and clinical trials have shown glucose and lipid-lowering effects of sevelamer, thereby giving rise to a potential role of the drug in the treatment of patients with type 2 diabetes. These 'novel' effects are most probably derived from the bile acid-binding properties of sevelamer. The proposed potential is supported by the approval of the bile acid sequestrant colesevelam in the United States for the treatment of type 2 diabetes and hypercholesterolaemia. This article offers a brief review on the effects of sevelamer and a perspective on the potential mechanisms behind the glucose-lowering effect of the drug.

Original language	English
Journal	Diabetes, Obesity and Metabolism
Volume	17
Issue number	2
Pages (from-to)	116-120
Number of pages	5
ISSN	1462-8902
DOIs	https://doi.org/10.1111/dom.12355
Publication status	Published - 1 Feb 2015

Bibliographical note

Publisher Copyright:
© 2014 John Wiley & Sons Ltd.

Keywords

Bile acid sequestrant
Chronic kidney disease
Diabetes
HbA1c
Phosphate resin

Access to Document

10.1111/dom.12355

Cite this

@article{9601088c9d2b4a2488d8a9a170de71e0,

title = "Sevelamer in a diabetologist's perspective: A phosphate-binding resin with glucose-lowering potential",

abstract = "Sevelamer is a calcium-free and metal-free phosphate-binding oral drug used in the management of hyperphosphataemia in chronic kidney disease. Preclinical and clinical trials have shown glucose and lipid-lowering effects of sevelamer, thereby giving rise to a potential role of the drug in the treatment of patients with type 2 diabetes. These 'novel' effects are most probably derived from the bile acid-binding properties of sevelamer. The proposed potential is supported by the approval of the bile acid sequestrant colesevelam in the United States for the treatment of type 2 diabetes and hypercholesterolaemia. This article offers a brief review on the effects of sevelamer and a perspective on the potential mechanisms behind the glucose-lowering effect of the drug.",

keywords = "Bile acid sequestrant, Chronic kidney disease, Diabetes, HbA1c, Phosphate resin",

author = "A. Br{\o}nden and M. Hansen and Sonne, {D. P.} and U. Rohde and T. Vilsb{\o}ll and Knop, {Filip K.}",

note = "Publisher Copyright: {\textcopyright} 2014 John Wiley & Sons Ltd.",

year = "2015",

month = feb,

day = "1",

doi = "10.1111/dom.12355",

language = "English",

volume = "17",

pages = "116--120",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Sevelamer in a diabetologist's perspective

T2 - A phosphate-binding resin with glucose-lowering potential

AU - Brønden, A.

AU - Hansen, M.

AU - Sonne, D. P.

AU - Rohde, U.

AU - Vilsbøll, T.

AU - Knop, Filip K.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Sevelamer is a calcium-free and metal-free phosphate-binding oral drug used in the management of hyperphosphataemia in chronic kidney disease. Preclinical and clinical trials have shown glucose and lipid-lowering effects of sevelamer, thereby giving rise to a potential role of the drug in the treatment of patients with type 2 diabetes. These 'novel' effects are most probably derived from the bile acid-binding properties of sevelamer. The proposed potential is supported by the approval of the bile acid sequestrant colesevelam in the United States for the treatment of type 2 diabetes and hypercholesterolaemia. This article offers a brief review on the effects of sevelamer and a perspective on the potential mechanisms behind the glucose-lowering effect of the drug.

AB - Sevelamer is a calcium-free and metal-free phosphate-binding oral drug used in the management of hyperphosphataemia in chronic kidney disease. Preclinical and clinical trials have shown glucose and lipid-lowering effects of sevelamer, thereby giving rise to a potential role of the drug in the treatment of patients with type 2 diabetes. These 'novel' effects are most probably derived from the bile acid-binding properties of sevelamer. The proposed potential is supported by the approval of the bile acid sequestrant colesevelam in the United States for the treatment of type 2 diabetes and hypercholesterolaemia. This article offers a brief review on the effects of sevelamer and a perspective on the potential mechanisms behind the glucose-lowering effect of the drug.

KW - Bile acid sequestrant

KW - Chronic kidney disease

KW - Diabetes

KW - HbA1c

KW - Phosphate resin

UR - http://www.scopus.com/inward/record.url?scp=84921436822&partnerID=8YFLogxK

U2 - 10.1111/dom.12355

DO - 10.1111/dom.12355

M3 - Review

C2 - 25041567

AN - SCOPUS:84921436822

VL - 17

SP - 116

EP - 120

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 2

ER -

Sevelamer in a diabetologist's perspective: A phosphate-binding resin with glucose-lowering potential

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Cite this